改良心理动力性心理治疗对精神分裂症谱系障碍的疗效:德国随机对照试验
在德国柏林单中心开展的前瞻性、评估者盲法、平行组随机对照试验中,130例18-64岁精神分裂症或分裂情感性障碍门诊患者按1:1随机接受MPP-S(至少30次)联合TAU或单纯TAU。意向性分析显示,MPP-S组在24个月和36个月时Mini-ICF-APP评分改善显著优于对照组,不良事件频率两组相似。
要点
- MPP-S联合TAU较单纯TAU在24个月和36个月时显著改善社会心理功能。
- 两组不良事件频率相似,但MPP-S组有1例自杀死亡(未开始心理治疗)和1例 forensic 住院。
- 结果支持心理动力性心理治疗作为精神分裂症谱系障碍的辅助治疗可能具有长期获益。
核心结论
- MPP-S联合TAU可能改善精神分裂症谱系障碍患者的社会心理功能,且可能具有长期获益。
研究设计与样本
- 前瞻性、单中心、评估者盲法、平行组随机对照试验,在德国柏林Charité圣赫德维希医院精神科大学医院开展。
- 主要结局为社会心理功能,采用Mini-ICF-APP评估,在基线、治疗后(24个月)和随访(36个月)评估,按意向性治疗原则分析。
主要发现
- 线性混合模型显示显著的组别×时间交互作用, favoring 干预组。
- 不良事件频率两组相似;严重不良事件共3例:MPP-S联合TAU组1例自杀死亡(未开始心理治疗)和1例 forensic 住院,单纯TAU组1例自杀死亡。
关键数值与推荐
- MPP-S为手动化治疗,最少30次,针对该人群的人际脆弱性。
临床怎么用
- 对于精神分裂症谱系障碍门诊患者,可考虑在常规治疗基础上联合MPP-S以改善社会心理功能。
- MPP-S可能作为其他心理治疗和社会心理治疗的补充角色。
局限性
- 单中心研究,样本量130例,可能限制普遍性。
- 参与者和治疗师未设盲,仅评估者盲法。
- 有生活经验者未正式参与研究设计、实施或报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with schizophrenia-spectrum disorders have difficulties in interpersonal functioning that remain insufficiently addressed by standard care. Despite long-standing clinical use, psychodynamic psychotherapy has little empirical support compared with other psychosocial treatments for people with schizophrenia-spectrum disorders. We evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S), a manualised treatment tailored to the interpersonal vulnerability characteristic of this population, plus treatment as usual (TAU), compared with TAU alone. METHODS: This prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial was conducted at the Psychiatric University Hospital of the Charité at St Hedwig Hospital in Berlin, Germany. Participants were outpatients aged 18-64 years who were diagnosed with schizophrenia or schizoaffective disorder and exclusion criteria included organic brain disorder, somatic illness affecting cerebral function, and current or past alcohol or illicit drug misuse requiring addiction-specific treatment. Participants were randomly assigned 1:1 in blocks of ten to MPP-S (minimum 30 sessions) plus TAU or TAU alone. Outcome assessors were masked, but participants and therapists were not. The primary outcome was psychosocial functioning, measured using the Mini International Classification of Functioning, Disability and Health Rating for Limitations of Activities and Participation in Psychological Disorders (Mini-ICF-APP) and evaluated at baseline and prespecified post-treatment (24 months) and follow-up (36 months) assessments. Analyses followed the intention-to-treat principle. Linear mixed models were used to analyse incomplete longitudinal data under a missing-at-random assumption. People with lived experience were not formally involved in the design, conduct, or reporting of this study. This trial was preregistered at ClinicalTrials.gov (NCT02576613) and is complete. FINDINGS: From Oct 12, 2015, to Dec 7, 2021, 130 participants (57 [44%] female and 73 [56%] male) were randomly assigned to either MPP-S plus TAU (n=65) or TAU alone (n=64). One participant withdrew consent to data analysis. Regarding the primary outcome of psychosocial functioning, linear mixed models showed significant group-by-time interactions favouring the intervention: estimated marginal means indicated adjusted between-group differences in Mini-ICF-APP scores of -3·45 (95% CI -5·51 to -1·40; p=0·0011) at 24 months and -4·07 (-6·19 to -1·94; p=0·0002) at 36 months. The frequency of adverse events was similar between groups. There were three serious adverse events: two participants died by suicide (one in the MPP-S plus TAU group who did not start psychotherapy and one in the TAU alone group) and one participant in the MPP-S plus TAU group was admitted to a forensic hospital. INTERPRETATION: MPP-S added to TAU could improve psychosocial functioning compared with TAU alone. Our findings suggest efficacy and possible long-term benefits of psychodynamic psychotherapy for schizophrenia-spectrum disorders and indicate its potential role alongside other psychotherapeutic and psychosocial treatments. FUNDING: Berlin Institute of Health, Deutsche Gesellschaft für Psychoanalyse, Psychotherapie, Psychosomatik und Tiefenpsychologie, International Psychoanalytic University Berlin, and Köhler-Stiftung.
引用
- Montag C, Bröcker AL, Bayer S, et al. The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial. Lancet Psychiatry. 2026. PMID: 42716057. doi:10.1016/S2215-0366(26)00240-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。